Breast Invasive Ductal Carcinoma
Associated Genetic Biomarkers
Breast invasive ductal carcinomas most frequently harbor alterations in TP53, PIK3CA, GATA3, ERBB2, and CCND1 .
PIK3CA Mutation, TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, and PIK3CA Codon 1047 Missense are the most common alterations in breast invasive ductal carcinoma .
There are 20 clinical trials for breast invasive ductal carcinoma, of which 18 are open and 2 are completed or closed. Of the trials that contain breast invasive ductal carcinoma as an inclusion criterion, 1 is early phase 1 (1 open), 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 4 are phase 2 (4 open), 3 are phase 3 (3 open), and 8 are no phase specified (7 open).
ER, HER2, and PR are the most frequent gene inclusion criteria for breast invasive ductal carcinoma clinical trials .
Radiation therapy, cyclophosphamide, and paclitaxel are the most common interventions in breast invasive ductal carcinoma clinical trials.
Significant Genes in Breast Invasive Ductal Carcinoma
ERBB2 is altered in 14.14% of breast invasive ductal carcinoma patients .
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for breast invasive ductal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and breast invasive ductal carcinoma as inclusion criteria, 1 is no phase specified (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.